Johnson & Johnson Firefly Bio Acquisition: JNJ Acquires Firelink DAC Platform for $1 Billion
Johnson & Johnson has announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash to secure its novel Firelinkâ„¢ degrader antibody conjugate platform.
